Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

686

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Trastuzumab Deruxtecan
DRUG: pembrolizumab
DRUG: Pemetrexed
DRUG: Chemotherapy

Sponsor

Daiichi Sankyo

Collaborators

[object Object]